WebMar 7, 2024 · SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced... WebJun 4, 2024 · Using its proprietary Tri-specific T cell Activating Construct (TriTAC ®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and...
Harpoon Therapeutics Reports Fourth Quarter and Full Year
WebMay 2, 2024 · Under this agreement, Harpoon is the sponsor of the anticipated clinical trials, and Roche will supply atezolizumab. About HPN328 HPN328 is a DLL3 targeting TriTAC ® being studied as a single... WebJun 2, 2024 · The drug, HPN328, was previously granted orphan drug designation for the treatment of SCLC. It targets DLL3, using Harpoon Therapeutics’ half-life extended TriTAC, which mitigates cytokine release syndrome (CRS) while maintaining clinical activity. 1. “DLL3 is expressed on the surface of tumor cells in more than 70% of small cell … cabinet secretary of india name
Study in Patients With Advanced Cancers Associated With …
WebMar 10, 2024 · In January 2024, Harpoon announced that the the first patient had been dosed in a Phase 1/2 clinical trial for HPN328, the company’s fourth TriTAC in clinical development. HPN328 targets... WebJan 11, 2024 · Using its proprietary Tri-specific T cell Activating Construct (TriTAC ®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and ... WebOct 29, 2024 · Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular … cabinet secretary pay scale